Evidence map›Paper›PMID 17163249›Full record

ReviewClinical drug investigation2006

Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler.

Henry Chrystyn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical drug investigation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Today's improvement in asthma treatment: role of MART and Easyhaler.Multidisciplinary respiratory medicine · 2020
    Article
  5. Review
  6. EasyhalerDrugs in context · 2019
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice.Primary care respiratory journal : journal of the General Practice Airways Group · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Henry ChrystynSchool of Pharmacy and Institute of Pharmaceutical Innovation, University of Bradford, Bradford, West Yorkshire, UK. H.Chrystyn@Bradford.ac.uk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The characteristics of an ideal inhaler are based around the design and formulation of the device, patient use and the clinical effect, together with concordance and patient preference. To ensure consistent drug delivery to the lungs, with regular adherence to the prescribed dosage regimen, it is essential that all these characteristics simultaneously interact to provide smooth and sustained therapeutic control affected only by the clinical status of the patient. The literature highlights that dose emission from an Easyhaler is fairly consistent irrespective of the inhalation technique used by patients of all age groups. Clinical studies have shown equivalence of this device to those frequently prescribed and that it is preferred by many patients. Although further research is required into the development of inhalation devices, the literature describing the Easyhaler dry powder inhaler indicates how an inhaler can closely meet the criteria for an ideal inhaler.

Indexed as

Patents as TopicAdministration, InhalationDrug Delivery SystemsHumansMetered Dose InhalersParticle SizePharmaceutical PreparationsPowdersPharmaceutical PreparationsPowders

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.